NCT03386760

Brief Summary

The investigators developed an ultra-speed picosecond laser (20ps) with a 20gHz repetition rate that provide very promising results in vitro and in ex vivo skin to remove skin tattoos. The aim of this study is to evaluate the efficacy and tolerance of a new ultra-speed picosecond laser and to compare it to a nanosecond laser for treating black tattoos. In a first phase of the study 10 patients with black tattoos will be treated with increasing fluencies of the picosecond laser to the optimal parameters in terms of efficacy and tolerance. In a second phase, 10 additional subjects with black tattoos will be treated after central randomization on half of the tattoo with the picosecond laser (with the parameters determined in the first phase) and the other half treated with a nanosecond laser.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
18

participants targeted

Target at P25-P50 for phase_1

Timeline
Completed

Started Jan 2018

Longer than P75 for phase_1

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 18, 2017

Completed
11 days until next milestone

First Posted

Study publicly available on registry

December 29, 2017

Completed
17 days until next milestone

Study Start

First participant enrolled

January 15, 2018

Completed
4.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 8, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 8, 2022

Completed
Last Updated

July 22, 2024

Status Verified

July 1, 2024

Enrollment Period

4.5 years

First QC Date

December 18, 2017

Last Update Submit

July 19, 2024

Conditions

Keywords

tattoo

Outcome Measures

Primary Outcomes (1)

  • Percentage of decrease of tattoos 2 months after the third session as compared to baseline on standardized pictures

    2 month after the end of laser utilisation

Secondary Outcomes (4)

  • Evaluation of Pain with EVA test

    2 months after one session of laser utilisation

  • Evaluation of tolerance

    2 months after one session of laser utilisation

  • satisfaction evaluation of depigmanetation tattoo

    2 months after one session of laser utilisation

  • Skin biopsies

    immediately after treatment

Study Arms (2)

A- Ultra-Speed Picosecond laser

EXPERIMENTAL

Utilisation of Ultra-speed Picosecond laser for tattoo depigmentation

Device: Laser Utilisation PicoSecond

B- Nanosecond laser

ACTIVE COMPARATOR

Utilisation of Nanosecond laser for tattoo depigmentation

Device: Laser Utilisation Nano-second

Interventions

Laser utilisation for tattoo depigmentation 1 session every month for a total of 3 sessions

A- Ultra-Speed Picosecond laser

Laser utilisation for tattoo depigmentation 1 session every month for a total of 3 sessions

B- Nanosecond laser

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Black tattoos with surface between 10 and 100 cm²
  • Skin type I to VI

You may not qualify if:

  • Childbearing age women
  • Active dermatosis located on the tattoo
  • Personal history of hypertrophic scars or keloids
  • Pigmentary or vascular lesions located on the tattoo
  • Subject taking oral steroid or retinoid or have any risk of delayed healing problems
  • Acquired or hereditary conditions that could leead to a delayed healing
  • Allergy to xylocaine, prilocaine or lidocaine

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU de Nice - Dermatologie - Hôpital Archet

Nice, 06200, France

Location

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 18, 2017

First Posted

December 29, 2017

Study Start

January 15, 2018

Primary Completion

July 8, 2022

Study Completion

July 8, 2022

Last Updated

July 22, 2024

Record last verified: 2024-07

Locations